

30 October 2024

Treatment of Wet AMD

- In the last 12 months of data that you have available, how many patients were treated for wet AMD (wet age-related macular degeneration) (ICD-10 Code H35.30) with the following agents:

Note for FOI Response below: Belfast Trust has recently moved to an electronic record system, which has had a temporary impact on the reporting mechanisms available for this information. We have provided the figures from 1 May 2024 to 5 June 2024 via our previous systems. The Information from 6 June 2024 to 31 August 2024 is provided via the new electronic record system, which does not provide the same level of data at this point. We will be able to provide this information in future requests.

- a. Bevacizumab 6
- b. Faricimab 1331
- c. Ranibizumab 607
- d. Aflibercept 3879

- If possible to answer, in the last 12 months of data that you have available, how many other ophthalmology patients have you treated with the following agents (please list how many for each agent separately):

Number of Injections/Implants: May to August 2024:
Medisoft figures 01/05/24 to 05/06/24

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	1489	234	397
Bevacizumab	0	0	0
Faricimab	460	266	<5
Ranibizumab - Lucentis	260	23	32
Ranibizumab - Ongavia	0	0	0
Ranibizumab - Ximluci	0	0	0

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

30 October 2024

Encompass (electronic record system) injection figures 06/06/24 to 31/08/24

Treatment	Total
Aflibercept	1759
Bevacizumab	6
Faricimab	603
Ranibizumab - Lucentis	292
Ranibizumab - Ongavia	0
Ranibizumab - Ximluci	0